Fig. 3: Improved RFB release by formulations containing uncapped acid-ending PLGA. | Nature Communications

Fig. 3: Improved RFB release by formulations containing uncapped acid-ending PLGA.

From: A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis

Fig. 3

a Daily in vitro RFB release from LA-RFB formulations containing acid-ending PLGA (LA:GA 50:50, MW 13.5 kDa) without Kolliphor®HS 15 (RFB14) or with Kolliphor®HS 15 (RFB14KH), n = 3 per formulation. b In vivo RFB plasma concentrations in BALB/c after a single subcutaneous injection (50 μL) of RFB14 or RFB14KH (n = 4). The dotted line indicates RFB MIC. c RFB tissue concentrations at 2 and 6 weeks post administration of RFB14KH (50 μL) in BALB/c mice; n = 4 per time point, mean ± SEM. d Tissue to plasma ratio of RFB concentrations at 2 and 6 weeks post administration of RFB14KH (n = 4 per time point, mean ± SEM). Spl: spleen, Kid: kidney, LN: lymph nodes. e Pharmacokinetics of RFB after a single subcutaneous administration of LA-RFB (50 μL) in BALB/c mice followed by a second injection of RFB14KH (50 μL) at 8 weeks (n = 4) or 12 weeks (n = 2) after the first dose. Mean and individual datapoints are shown; arrows indicate the time point of the booster injections, and the dotted line indicates RFB MIC. Source data are provided as a Source data file.

Back to article page